





## Myocardial-Derived Growth Factor Therapeutics

*“New Biological Tools for the Highly Innovative and Rapidly Growing Interventional Cardiology Market”*

	Generx	Corgentin
<b>Commercial Development</b>	Late Stage Phase 2b/3	Early-Stage Pre-Clinical
<b>Formulation</b>	mdFGF-4	mdIGF-1
<b>Intended Regenerative Biologic Effect</b>	Improved Blood Supply and Oxygen Delivery to Chronically Ischemic Myocardium	Inhibition of Apoptosis, Enhanced Angiogenesis, Positive Inotropy, Adaptive Cardiomyocyte Hypertrophy in Injured Myocardium
<b>Mechanism of Action</b>	Promote and Stimulate Angiogenic Growth of Collateral Circulation in Ischemic Heart Disease 	Improve Recovery of Injured Myocardium and Enhance Function Following Heart Attack 
<b>Initial Medical Indications</b>	Recurrent Angina Pectoris due to Coronary Artery Disease ≈ 2.0 Million U.S. Patients	Acute Coronary Syndrome Adjunctive Treatment Following Percutaneous Coronary Intervention ≈ 500,000 U.S. Patients
<b>Clinical Application</b>	Administration in Catheterization Laboratory Setting by Interventional Cardiologists	Administration in Catheterization Laboratory Setting Immediately Following Acute Intervention for Heart Attack
<b>Delivery Approach</b>	One-Time Intracoronary Administration Using Standard Diagnostic Catheter Effecting Localized & Sustained Myocardial-Derived FGF-4 Protein	One-Time Intracoronary Administration Using Standard Diagnostic Catheter Effecting Localized & Sustained Myocardial-Derived IGF-I Protein